Perrigo | PRGO - Cash And Equivalent


Perrigo reported $357.2M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Abbott USD 6.8B 1.72B Mar/2026
Bayer EUR 4.29B 1.44B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Coherus Biosciences USD 82.92M 32.32M Jun/2026
Corcept Therapeutics USD 111.04M 2.3M Jun/2026
Dr.Reddys Laboratories INR 11.2B 4.16B Jun/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
J&J USD 20.42B 1.27B Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Nestle CHF 3.55B 1.03B Jun/2026
Pacira USD 205.88M 61.57M Jun/2026
Perrigo USD 357.2M 174.4M Mar/2026
Pfizer USD 976M 727M Jun/2026
Phibro Animal Health USD 61.42M 6.49M Jun/2026
Prestige Brands USD 89.13M 25.26M Jun/2026
Reckitt Benckiser GBP 880M 106M Dec/2024
Sanofi EUR 6.35B 806M Jun/2026
Supernus Pharmaceuticals USD 179.95M 4.92M Jun/2026
Teva Pharmaceutical Industries USD 3.74B 185M Mar/2026
Xeris Pharmaceuticals USD 121.75M 10M Jun/2026
Zoetis USD 1.48B 465M Jun/2026